A detailed history of Principal Securities, Inc. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Principal Securities, Inc. holds 15 shares of PTGX stock, worth $687. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15
Previous 6 150.0%
Holding current value
$687
Previous $208,000 224.52%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$33.72 - $47.33 $303 - $425
9 Added 150.0%
15 $675,000
Q4 2023

Feb 07, 2024

BUY
$14.05 - $23.44 $84 - $140
6 New
6 $138,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Principal Securities, Inc. Portfolio

Follow Principal Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Principal Securities, Inc. with notifications on news.